Cart
sales@molnova.com
hVEGF-IN-1
CAS No. 1637443-98-1
hVEGF-IN-1( —— )
Catalog No. M17352 CAS No. 1637443-98-1
hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 126 | In Stock |
|
| 10MG | 179 | In Stock |
|
| 25MG | 301 | In Stock |
|
| 50MG | 427 | In Stock |
|
| 100MG | 597 | In Stock |
|
| 200MG | 806 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamehVEGF-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionhVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
-
DescriptionhVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
-
In VitrohVEGF-IN-1 (compound 1) (1 nM-100 μM; 5 min) binds to IRES-A (WT) and IRES-A mutant RNA oligomer (IRES-MU1) with Kds of 1.29 and 13.4 μM by microscale thermophoresis (MST) measurements, respectively. hVEGF-IN-1 (0.375-3 μM; 0-24 h) reduces MDA-MB-231 cell migration approximately 25% at the concentration of 3 μM.hVEGF-IN-1 (0.1875-3 μM; 48 h) reduces the level of VEGF-A protein in MCF-7 cells.hVEGF-IN-1 (0.375-3 μM; 48 h) decreases the relative wound closure of migrated MCF-7 cells by ～35% at the concentration of 3 μM.hVEGF-IN-1 (1.25-10 μM) reduces the stability of the IRES-A G-Quadruplex in a dose-dependent manner. Western Blot Analysis Cell Line:MCF-7 cells Concentration:0.1875, 0.375, 0.75, 1.5, 3 μM Incubation Time:48 hours Result:Down-regulated hVEGF-A expression.
-
In VivohVEGF-IN-1 (compound 1) (7.5 mg/kg; i.p. once daily for 20 d) inhibits tumor growth in a human breast tumor xenograft. Animal Model:BALB/c female nude mice were implanted MCF-7 cells Dosage:7.5 mg/kg Administration:I.p. once daily for 20 days Result:Reduced the tumor volume to <300 mm3.Reduced the tumor weight around 60.1% to a final weight of 0.18 g.Decreased the VEGF-A level in tumor tissue.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorVEGF-A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1637443-98-1
-
Formula Weight581.75
-
Molecular FormulaC34H43N7O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 25 mg/mL42.97 mM;H2O : < 0.1 mg/mL
-
SMILESCCN(CC)CCOc1ccc(cc1)Nc1nc(c2c(NC(=O)CCN3CCN(C)CC3)cccc2)nc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Fibrinopeptide A, hu...
Fibrinopeptide A, human is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH2-termini of the Aα chain.The conversion of monomeric fibrinogen into polymeric fibrin is mediated by thrombin, which binds to the central region of fibrinogen and catalyzes cleavage of the 2 short peptides, the 16-residue fibrinopeptide A (FpA) and the 14-residue fibrinopeptide B (FpB), located at the NH2-termini of the Aα and Bβ chains, respectively.
-
CycLuc1
CycLuc1 is a brain penetrant luciferase substrate.
-
3,4,5-Tricaffeoylqui...
3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.
